inspection – Page 79

CAPA system overloaded during inspection readiness – building an inspection-resilient QMS

Creating a Resilient CAPA System for Inspection Readiness in Pharmaceutical Quality Management Pharmaceutical professionals know the challenges of maintaining an effective Corrective and Preventive Action (CAPA) system, particularly when facing…

Hybrid paper-electronic workflows uncontrolled during system operation – inspection evidence requirements

Managing Uncontrolled Hybrid Paper-Electronic Workflows in Pharmaceutical Operations In today’s pharmaceutical landscape, integrating hybrid paper-electronic workflows has become a necessity. However, uncontrolled workflows during system operation can lead to significant…

Change management weak during QMS redesign – CAPA governance model

Effective Strategies for Strengthening Change Management During QMS Redesign The pharmaceutical industry is undoubtedly intricate, with regulatory bodies steadfastly enforcing stringent quality and compliance standards. During a Quality Management System…

Shared user credentials during laboratory walkthrough – 483 risk assessment

Risk Assessment for Shared User Credentials During Laboratory Walkthroughs In the pharmaceutical manufacturing sector, maintaining robust data integrity is critical to compliance with Good Distribution Practices (GDP) and the tenets…

Poor QMS metrics during QMS redesign – CAPA governance model

Addressing Challenges in Quality Management System Redesign: A CAPA Governance Approach In the pharmaceutical sector, redesigning a Quality Management System (QMS) can often expose weaknesses in existing metrics, leading to…

Manual data transcription without verification during FDA inspection – 483 risk assessment

Assessing Risks of Manual Data Transcription Without Verification During FDA Inspections As pharmaceutical manufacturing and quality professionals, encountering challenges surrounding data integrity is not new. One of the significant issues…

Ineffective deviation management during QMS redesign – building an inspection-resilient QMS

“`html Addressing Ineffective Deviation Management During QMS Redesign for an Inspection-Resilient System The redesign of a Quality Management System (QMS) is an important phase for any pharmaceutical manufacturer aiming to…

Shared user credentials during internal audit – 483 risk assessment

Risk Assessment for Shared User Credentials During Internal Audits In today’s highly regulated pharmaceutical environment, the integrity of data and compliance with Good Manufacturing Practices (GMP) is paramount. The use…

Management review ineffective during routine operations – metrics inspectors question

Addressing Ineffective Management Reviews During Routine Operations for Inspection Readiness In today’s highly regulated pharmaceutical environment, management reviews play a crucial role in maintaining compliance and ensuring product quality. However,…

Inadequate DI governance during system validation – CAPA effectiveness checks

Managing Inadequate Data Integrity Governance During System Validation: A Practical Playbook for Pharma Professionals In an era where regulatory scrutiny is intensifying, inadequate data integrity governance during system validation poses…

Fragmented QMS processes during inspection readiness – building an inspection-resilient QMS

Building an Inspection-Resilient Quality Management System Against Fragmented QMS Processes In the highly regulated pharmaceutical manufacturing landscape, fragmented Quality Management System (QMS) processes can lead to significant compliance risks, especially…

Repeat data integrity lapses during laboratory walkthrough – remediation roadmap regulators expect

Remediation Roadmap for Recurring Data Integrity Lapses Observed During Laboratory Walkthroughs Data integrity is pivotal in pharmaceutical manufacturing and laboratory settings, especially against the backdrop of increasing regulatory scrutiny. When…